{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:59:34Z","timestamp":1781243974783,"version":"3.54.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B e antigen (HBeAg) loss with anti-HBe appearance marks the first durable immunological milestone during nucleos(t)ide analogues (NAs) therapy, yet static baseline or single time-point biomarkers anticipate this event poorly. We hypothesized that early dynamic parameters reflecting viral, antigenic and hepatic function during the first 12 weeks of therapy contain richer prognostic information than baseline values alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to construct a model that fuses week-12 changes in serum biochemical and virological parameters and tested its performance in predicting week-60 HBeAg seroconversion (SR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum biochemical and virological parameters of HBeAg-positive patients receiving NAs treatment between January and December 2023 were collected. Difference, ratio and absolute week-12 values of variables were derived. After ten-fold cross-validation, a multi-variable signature was selected to build a least absolute shrinkage and selection operator (LASSO) logistic regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 38.24% (26\/68) of patients achieved HBeAg SR. Using LASSO regression with ten-fold cross-validation, an eight-variable signature related to the dynamic changes of HBeAg, hepatitis B surface antigen (HBsAg), gamma-glutamyl transferase (GGT), and albumin (ALB) were selected. In the training cohort (n=68), the multi- variable model demonstrated an area under the curve (AUC) of 0.975 (sensitivity, 96.2%; specificity, 95.2%), significantly outperforming single-variable models. In the test cohort (n=34), the model achieved an AUC of 0.721 with maintained high specificity (95%) and positive predictive value (PPV, 90%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early on-treatment integrated dynamics of HBeAg, HBsAg, GGT and ALB showed predictive value for subsequent HBeAg SR. The eight-variable model may assist monitoring or alternative strategies in patients receiving treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1816265","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:46:12Z","timestamp":1781243172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early on-treatment dynamics predicting hepatitis B e antigen seroconversion in chronic hepatitis B"],"prefix":"10.3389","volume":"17","author":[{"given":"Kai","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaguo","family":"Shao","sequence":"additional","affiliation":[{"name":"Xixi Hospital Biobank (Clinical Data Resource Center), Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shourong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People\u2019s Hospital)","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.053","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2025","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.006","article-title":"Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study","volume":"56","author":"Lau","year":"2012","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2570","article-title":"Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune-tolerant phase of chronic hepatitis B virus infection: A systematic review and meta-analysis","volume":"34","author":"Liu","year":"2024","journal-title":"Rev Med Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000697376.56943.de","article-title":"Screening for hepatitis B virus infection in nonpregnant adolescents and adults: updated evidence report and systematic review for the US preventive services task force","volume":"324","author":"Chou","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.017","article-title":"A critique and systematic review of the clinical utility of hepatitis B core-related antigen","volume":"78","author":"Adraneda","year":"2023","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.040","article-title":"The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy","volume":"75","author":"Berg","year":"2021","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109698","article-title":"Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study","volume":"122","author":"Zheng","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra-long-term follow-up of interferon alfa treatment for HBeAg-positive chronic hepatitis B virus infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s163038","article-title":"Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs","volume":"11","author":"Cai","year":"2018","journal-title":"Infect Drug Resist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892031","article-title":"Dynamic changes of cytokine profiles and virological markers associated with HBsAg loss during peginterferon alpha-2a treatment in HBeAg-positive chronic hepatitis B patients","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14566","article-title":"Distinct T-cell receptor profiles associated with hepatitis B e antigen seroconversion during entecavir treatment","volume":"40","author":"Lian","year":"2020","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12985-025-02689-8","article-title":"Altered LY6E and TRIM6 expression in PBMCs correlated with HBsAg clearance and response to Peg-IFN-alpha treatment in HBeAg-negative chronic hepatitis B patients","volume":"22","author":"Shan","year":"2025","journal-title":"Virol J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29670","article-title":"Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B","volume":"96","author":"Lai","year":"2024","journal-title":"J Med Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2023.00320","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2025.11226\/2025","article-title":"Serum hepatitis B virus RNA as a predictive biomarker for HBeAg seroconversion during entecavir and tenofovir disoproxil fumarate therapy in chronic hepatitis B patients","volume":"117","author":"Wu","year":"2025","journal-title":"Rev Esp Enferm Dig"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000002946","article-title":"Predictive value of serum HBV RNA on HBeAg seroconversion in treated chronic hepatitis B patients","volume":"37","author":"Liu","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1539300","article-title":"Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B","volume":"13","author":"Hong","year":"2025","journal-title":"Front Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70510","article-title":"Paternally expressed gene 10 promoter methylation level as a predictor of HBeAg seroconversion in chronic hepatitis B patients","volume":"97","author":"Luo","year":"2025","journal-title":"J Med Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01344-25","article-title":"TUBB1 promoter methylation is a promising biomarker for predicting HBeAg seroconversion in chronic hepatitis B","volume":"13","author":"Zhao","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000028443","article-title":"Characteristics of peripheral blood gamma-glutamyl transferase in different liver diseases","volume":"101","author":"Xing","year":"2022","journal-title":"Med Baltimore"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00525","article-title":"Assessment of liver function for evaluation of long-term outcomes of intrahepatic cholangiocarcinoma: a multi-institutional analysis of 620 patients","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.1451","article-title":"Hypoalbuminemia: pathogenesis and clinical significance","volume":"43","author":"Soeters","year":"2019","journal-title":"JPEN J Parenteral Enteral Nutr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1816265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:46:13Z","timestamp":1781243173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1816265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1816265"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1816265","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1816265"}}